Medicare Enrolled
Dr. Clinton Haley, M.D.
Infectious Disease · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Haley from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Haley?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Haley
Dr. Clinton Haley is an infectious disease specialist in Dallas, TX, with 17 years of NPI registration. Based on federal Medicare data, Dr. Haley performed 34,453 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Haley received a total of $15,495 from 38 pharmaceutical and/or device companies across 834 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Haley is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years of NPI registration
▲ Top 4% volume in TX
$15,495 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗34,453
Medicare services
Top 4% in TX for infectious disease
Not available
Unique patients (not deduplicated)
$22
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 30,841 | $18 | $50 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,175 | $62 | $202 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
708 | $10 | $59 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
417 | $78 | $279 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
309 | $49 | $394 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
197 | $99 | $444 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
190 | $6 | $41 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
177 | $137 | $546 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
137 | $93 | $289 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
96 | $21 | $102 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
70 | $43 | $185 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
54 | $103 | $372 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $117 | $433 |
| Infusion tube insertion with imaging guidance A radiologist inserts an infusion tube into the body while using imaging guidance to ensure proper placement and reviews the procedure. |
21 | $313 | $1,225 |
| Home health agency supervision, complex multidisciplinary care Supervision by a physician or allowed practitioner for a patient receiving Medicare-covered services from a participating home health agency. This involves complex and multidisciplinary care modalities, with the patient not present during the supervision. |
17 | $83 | $303 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
15 | $19 | $57 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.5% high complexity
92.4% medium
6.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$15,495
Total received (2018-2024)
Avg $2,214/year across 7 years
Top 11% in TX for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
834
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,596
2023
$2,906
2022
$2,623
2021
$1,482
2020
$906
2019
$2,322
2018
$1,661
Payments by company (2024)
ViiV Healthcare Company
$1,172
Merck Sharp & Dohme LLC
$295
Gilead Sciences, Inc.
$271
ABBVIE INC.
$239
Insmed, Inc.
$231
EMD Serono, Inc.
$226
Paratek Pharmaceuticals, Inc.
$156
Shionogi Inc
$151
Ferring Pharmaceuticals Inc.
$145
Takeda Pharmaceuticals U.S.A., Inc.
$143
Napo Pharmaceuticals Inc
$132
AIMMUNE THERAPEUTICS, INC.
$107
Theratechnologies Inc.
$104
La Jolla Pharmaceutical Company
$66
HOSPIRA, INC.
$53
Octapharma USA, Inc.
$30
Melinta Therapeutics, LLC
$29
Invivyd Inc
$26
Astellas Pharma US Inc
$21
Top 3 companies account for 48.3% of 2024 payments
All-time payments by company (2018-2024) ›
ViiV Healthcare Company
$4,833
Gilead Sciences, Inc.
$968
Insmed, Inc.
$948
Janssen Biotech, Inc.
$895
Astellas Pharma US Inc
$755
EMD Serono, Inc.
$724
Merck Sharp & Dohme LLC
$716
Paratek Pharmaceuticals, Inc.
$649
Merck Sharp & Dohme Corporation
$607
ABBVIE INC.
$530
Shionogi Inc
$490
Theratechnologies Inc.
$408
Napo Pharmaceuticals Inc
$334
Cumberland Pharmaceuticals, Inc.
$258
Ferring Pharmaceuticals Inc.
$250
Takeda Pharmaceuticals U.S.A., Inc.
$240
AIMMUNE THERAPEUTICS, INC.
$195
La Jolla Pharmaceutical Company
$170
Melinta Therapeutics, Inc.
$154
Janssen Products, LP
$154
Grifols USA, LLC
$151
Allergan Inc.
$148
MAYNE PHARMA INC.
$138
Amgen Inc.
$109
TETRAPHASE PHARMACEUTICALS, INC.
$106
PFIZER INC.
$71
Melinta Therapeutics, LLC
$71
GlaxoSmithKline, LLC.
$68
Mayne Pharma Inc.
$68
HOSPIRA, INC.
$53
Nabriva Therapeutics, plc
$53
Amarin Pharma Inc.
$46
AbbVie Inc.
$44
Octapharma USA, Inc.
$30
Invivyd Inc
$26
Mylan Pharmaceuticals Inc.
$15
INSYS Therapeutics Inc
$11
Dynavax Technologies Corporation
$11
Top 3 companies account for 43.6% of all-time payments
Associated products mentioned in payments ›
AMBISOME · APRETUDE · AVYCAZ · Arikayce · BENLYSTA · Baxdela · CABENUVA · CRESEMBA · Caldolor · Cresemba · DALVANCE · DELSTRIGO · DIFICID · DORYX · DOVATO · Descovy · EGRIFTA · EVENITY · Fetroja · GATTEX · Gamunex-C · HYQVIA · Heplisav-B · INFLECTRA · ISENTRESS · JULUCA · Kimyrsa · LIVTENCITY · MYCAMINE · Mytesi · NOXAFIL · NUZYRA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · Orbactiv · PANZYGA · PEMGARDA · PIFELTRO · PREVNAR - 13 · PREVYMIS · PREZCOBIX · PREZISTA · REBYOTA · RUKOBIA · Rezzayo · SEROSTIM · SHINGRIX · SYMTUZA · SYNDROS · Serostim · Symfi Lo · Symtuza · TEFLARO · TIVICAY · TOLSURA · TRIUMEQ · TROGARZO · Truvada · VIBATIV · VOWST · Vabomere · Vascepa · Vibativ · XERAVA · Xembify · Xenleta · Xerava · ZENPEP · ZERBAXA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Infectious diseases in nearby ZIP areas
120
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Haley is a mixed practice specialist, with above-average Medicare volume (top 4% in TX), with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Haley experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Haley performed 30,841 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Haley receive payments from pharmaceutical companies?
Yes. Dr. Haley received a total of $15,495 from 38 companies across 834 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Haley's costs compare to other infectious diseases in Dallas?
Dr. Haley's average Medicare payment per service is $22. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Haley) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Dallas
Browse infectious diseases in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in TX
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in TX
Which TX infectious diseases receive the most from drug and device companies.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
Insmed, Inc. Payments to Doctors
See all physicians who received payments from Insmed, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology